Merck Provides Update on Keytruda (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
KENILWORTH, N.J.--(BUSINESS WIRE) July 1, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Canada Health | Cancer | Cancer & Oncology | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Merck | Pharmaceuticals | USA Health